Search research articles
Contact Us
Filters
Showing results (171-180 of 203) with videos related to
Page
of 21
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 20, 2022
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia A M Fulgenzi, et al.
JHEP Reports : Innovation in Hepatology
|
December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 28, 2022
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study
Thomas Talbot, Antonio D'Alessio, Matthias Pinter, et al.
Hepatology (Baltimore, Md.)
|
March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study
Antonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.
World Journal of Gastrointestinal Oncology
|
December 11, 2023
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Sirish Dharmapuri, Umut Özbek, Hiren Jethra, et al.
Hepatology Communications
|
October 27, 2023
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
Vincent Joerg, Bernhard Scheiner, Antonio D Alessio, et al.
JHEP Reports : Innovation in Hepatology
|
February 4, 2026
Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity
Ignazio Piseddu, Leonie S Jochheim, Katrin Boettcher, et al.
Cancers
|
December 11, 2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Yue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, et al.
Hepatology Communications
|
November 4, 2024
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort
Tiago de Castro, Sabrina Welland, Leonie Jochheim, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, et al.
Page
of 21
Search research articles
Search
Showing results (171-180 of 203) with videos related to
Sort By:
Page
of 21
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 20, 2022
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia A M Fulgenzi, et al.
JHEP Reports : Innovation in Hepatology
|
December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 28, 2022
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study
Thomas Talbot, Antonio D'Alessio, Matthias Pinter, et al.
Hepatology (Baltimore, Md.)
|
March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study
Antonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.
World Journal of Gastrointestinal Oncology
|
December 11, 2023
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Sirish Dharmapuri, Umut Özbek, Hiren Jethra, et al.
Hepatology Communications
|
October 27, 2023
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
Vincent Joerg, Bernhard Scheiner, Antonio D Alessio, et al.
JHEP Reports : Innovation in Hepatology
|
February 4, 2026
Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity
Ignazio Piseddu, Leonie S Jochheim, Katrin Boettcher, et al.
Cancers
|
December 11, 2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Yue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, et al.
Hepatology Communications
|
November 4, 2024
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort
Tiago de Castro, Sabrina Welland, Leonie Jochheim, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, et al.
Page
of 21